Mickey Kosloff

This paper develops an engineered nanobody inhibitor to control opioid receptor function with subcellular precision and demonstrates its effectiveness in vivo.

The paper investigates the molecular mechanism of the Gαo E246K mutation in neurodevelopmental disorders, showing it disrupts the GTPase cycle by impairing Gβγ dissociation, leading to dominant-negative effects.

This paper identifies and validates non-covalent inhibitors of RGS14 GAP activity using structure-guided virtual screening and machine learning, showing improved potency and CNS penetration.

The paper identifies structural elements in Gαs that prevent interactions with RGS proteins, showing three residues in the GTPase domain are necessary and sufficient for this resistance.

The paper compares structural conservation and divergence across 245 RTK extracellular domains from 54 RTKs, revealing inter-family similarities and unexpected structural differences.

This study identifies residue-level differences in G13 interactions with p115RhoGEF and PDZRhoGEF, revealing molecular determinants of their differential recruitment and providing insights for targeted therapeutic strategies.

This study identifies structural mechanisms explaining how certain RET mutations cause both Hirschsprungs disease and MEN2A by disrupting protein structure and promoting dimerization.

This study identifies GABAB receptor homologs in Nematostella vectensis and shows that activating GABABR signaling inhibits neurogenesis and disrupts nervous system development.